EMERYVILLE, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced the closing of a $70 million Series A financing and the appointment of industry veteran Chris Boulton as Chief Executive Officer. The financing was co-led by 5AM Ventures and OrbiMed, along with Monograph Capital. The capital will be used to advance Prolynx's proprietary pipeline of extended-duration incretin and non-incretin therapies designed to enable monthly and quarterly dosing towards IND enablement and clinical proof-of-concept.

The Company's approach to half-life extension utilizes a proprietary technology that has previously demonstrated clinical proof-of-concept in oncology, providing a de-risked foundation for the development of optimized, ultra-long-acting peptide therapeutics specifically engineered for obesity and related metabolic diseases.

Redefining the Standard of Care

"Current GLP1-based therapies have revolutionized obesity treatment, yet they still require weekly administration, and patients often experience significant tolerability issues due to suboptimal pharmacokinetics," said Chris Boulton. "By leveraging insights from our foundational platform, we are developing a portfolio of once-monthly and once-quarterly medicines designed to improve adherence, tolerability, and outcomes for patients. I look forward to working with Dan Santi, the team, and our high-quality investor syndicate to bring these highly differentiated assets to the clinic."

Boulton brings more ...